title: Arthralgia as an adverse event to infliximab: a reactive arthritis or triggering of psoriatic arthritis? Successful management by switching to etanercept.
authors.forename: A E
authors.initials: AE
authors.lastname: Moustou
authors.forename: A J
authors.initials: AJ
authors.lastname: Stratigos
authors.forename: T
authors.initials: T
authors.lastname: Vergou
authors.forename: S
authors.initials: S
authors.lastname: Gregoriou
authors.forename: S
authors.initials: S
authors.lastname: Georgala
authors.forename: I
authors.initials: I
authors.lastname: Danopoulou
mesh_terms: D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000627:therapeutic use; D018501:Antirheumatic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D018771:Arthralgia / Q000139:chemically induced* / Q000175:diagnosis; D015535:Arthritis, Psoriatic / Q000139:chemically induced* / Q000175:diagnosis; D016918:Arthritis, Reactive / Q000139:chemically induced* / Q000175:diagnosis; D003937:Diagnosis, Differential; D000068800:Etanercept; D006801:Humans; D007074:Immunoglobulin G / Q000009:adverse effects* / Q000627:therapeutic use; D000069285:Infliximab; D008297:Male; D008875:Middle Aged; D011565:Psoriasis / Q000188:drug therapy; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use; D012720:Severity of Illness Index; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
chemical_list: D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab; D000068800:Etanercept